Biogen Idec Inc (BIIB) 303.67 $BIIB
Stocks Rise; Apple, Microsoft Steady In Post-Session
at Investor's Business Daily - Tue Jul 22, 4:20PM CDT
Stocks rose Tuesday, rebounding from the prior day's losses, amid positive earnings and economic reports. The Nasdaq rose 0.7%, the S&P 500 climbed 0.5% and the Dow Jones industrial average added 0.4%. Volume was higher across the board in the stock...
Could This 1 Lawsuit Destroy Biogen Idec Stock?
Todd Campbell, The Motley Fool - Motley Fool - Tue Jul 22, 4:01PM CDT
Source: Biogen IDEC. Biogen 's Tecfidera launched a year ago, and it has already become a blockbuster likely to notch more than $2 billion in sales this year. Much of Tecfidera's success is coming at the expense of recently launched oral multiple...
Will Biogen Idec Inc. (BIIB) Surprise this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 22, 12:50PM CDT
Biogen Idec Inc. (BIIB) is scheduled to report its second-quarter 2014 results before the opening bell on Jul 23.
Alexion, 3 Other Top Biotechs Reporting Earnings
at Investor's Business Daily - Tue Jul 22, 11:42AM CDT
The four highest-rated of the market's seven big-cap biotechs are set to report second-quarter earnings this week, each with its own unique storyline. Biogen Idec (BIIB), the subject of Tuesday's New America, will be first to report before the open...
Over Half of Audited Multiple Sclerosis Patients Currently Treated with Biogen Idec's Tecfidera Have Experienced Minor Side Effects Although Impact on Use Appears Muted
PR Newswire - Tue Jul 22, 11:00AM CDT
Decision Resources Group finds that over half of audited multiple sclerosis (MS) patients currently treated with Biogen Idec's oral disease-modify therapy (DMT) Tecfidera have ever experienced flushing and/or gastrointestinal events while on the therapy. However, few Tecfidera-treated patients are currently experiencing these side effects, signifying either their transient nature or the effective medical management of such events. In the end, fewer than 15 percent of surveyed neurologists felt that Tecfidera-related side effects were an obstacle to their prescribing of the product.
Stocks Climb In Solid Trade; Chipotle Gaps Up, Breaks Out
at Investor's Business Daily - Tue Jul 22, 9:32AM CDT
Stocks stepped higher in firm volume Tuesday on a generally positive swell of earnings and economic news. The Nasdaq jumped 0.9% in early trade, with biotechs Alexion Pharmaceuticals (ALXN), Celgene (CELG) and Biogen (BIIB) leading the Nasdaq 100....
Is a Surprise Coming for Biogen Idec (BIIB) This Earnings Season? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 22, 7:44AM CDT
Biogen Idec (BIIB) looks poised to beat at earnings season. That is because Biogen Idec is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Oil Dominates; Keurig, Constellation Near Buy Points
at Investor's Business Daily - Mon Jul 21, 5:51PM CDT
Notable names dropping out of the Big Cap 20 this week include Biogen (BIIB) and Chipotle Mexican Grill (CMG), while new entrants include Canadian Pacific Railway (CP) and Magna International (MGA). Oil and gas continue to dominate this week's list,...
Isis Pharma Initiates Phase II Study on ISIS-APO(a) - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 21, 5:50PM CDT
Isis Pharmaceuticals, Inc. (ISIS) initiated a phase II study on ISIS-APO(a) in patients suffering from high lipoprotein(a) -- Lp(a).
IBD 50 Ends Week Lower But Skyworks Soars
at Investor's Business Daily - Mon Jul 21, 5:47PM CDT
The IBD 50 fell for a second straight week amid the market's recent turbulence as biotech stocks sold off. But many leading stocks continue to hold up well, and few have flashed sell signals. The index of top growth stocks fell 0.6% for the week,...
Alkermes' Pipeline Development Impresses, Key Updates Ahead - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 21, 3:40PM CDT
Alkermes (ALKS) announced the commencement of a phase I study on ALKS 8700.
Biogen Shares Rebound As Street Has A Change Of Heart
at Investor's Business Daily - Mon Jul 21, 3:09PM CDT
Biogen Idec heads into its second-quarter earnings report on one of its best rolls in years, as the biotech continues to benefit from heavy demand for its drugs to treat multiple sclerosis, cancer and autoimmune diseases. The No. 3 biotech by market...
Yellen Hates Biotech Stocks! Should You?
Brian Orelli, The Motley Fool - Motley Fool - Mon Jul 21, 1:01PM CDT
Federal Reserve Chairwoman Janet Yellen thinks your small-cap biotech is overvalued. The Fed's Monetary Policy Report, released on July 15, had this to say: [V]aluation metrics in some sectors do appear substantially stretched -- particularly...
Amgen's AMG 416 Succeeds in Phase III, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 21, 12:23PM CDT
Amgen Inc. (AMGN) announced that AMG 416 (formerly known as velcalcetide) has met the primary as well as secondary endpoints in a phase III study.
Ultragenyx (RARE) Jumps: Stock Moves 7.8% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 21, 8:25AM CDT
Ultragenyx (RARE) was a big mover last session, with shares rising nearly 8% on the day.
bluebird bio, Inc. (BLUE) in Focus: Stock Surges 10.24% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 21, 7:44AM CDT
bluebird bio, Inc. (BLUE) was a big mover last session, as the company saw its shares surge over 10% on the day.
Facebook, Gilead Headline IBD 50's Top 5 Earnings
at Investor's Business Daily - Sat Jul 19, 7:02AM CDT
With earnings season in full force, investors should focus on the very best companies. The elite IBD 50 ranks top-rated growth stocks, factoring in strong relative price strength and top fundamentals. The IBD 50 has several companies reporting...
Why the Market is Wrong About Baxter Stock
Stephen D., Simpson,, The Motley Fool - Motley Fool - Fri Jul 18, 7:59AM CDT
Diversified health care player Baxter has done alright so far this year, up almost 10% and ahead of the S&P 500, but there is still a fair bit of skepticism on the name. Analysts continue to fret that Biogen Idec ...
Stocks Rise; Apple, Microsoft Steady In Post-Session
at Investor's Business Daily - Tue Jul 22, 4:20PM CDT
Stocks rose Tuesday, rebounding from the prior day's losses, amid positive earnings and economic reports. The Nasdaq rose 0.7%, the S&P 500 climbed 0.5% and the Dow Jones industrial average added 0.4%. Volume was higher across the board in the stock...
Could This 1 Lawsuit Destroy Biogen Idec Stock?
Todd Campbell, The Motley Fool - Motley Fool - Tue Jul 22, 4:01PM CDT
Source: Biogen IDEC. Biogen 's Tecfidera launched a year ago, and it has already become a blockbuster likely to notch more than $2 billion in sales this year. Much of Tecfidera's success is coming at the expense of recently launched oral multiple...
Will Biogen Idec Inc. (BIIB) Surprise this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 22, 12:50PM CDT
Biogen Idec Inc. (BIIB) is scheduled to report its second-quarter 2014 results before the opening bell on Jul 23.
Alexion, 3 Other Top Biotechs Reporting Earnings
at Investor's Business Daily - Tue Jul 22, 11:42AM CDT
The four highest-rated of the market's seven big-cap biotechs are set to report second-quarter earnings this week, each with its own unique storyline. Biogen Idec (BIIB), the subject of Tuesday's New America, will be first to report before the open...
Over Half of Audited Multiple Sclerosis Patients Currently Treated with Biogen Idec's Tecfidera Have Experienced Minor Side Effects Although Impact on Use Appears Muted
PR Newswire - Tue Jul 22, 11:00AM CDT
Decision Resources Group finds that over half of audited multiple sclerosis (MS) patients currently treated with Biogen Idec's oral disease-modify therapy (DMT) Tecfidera have ever experienced flushing and/or gastrointestinal events while on the therapy. However, few Tecfidera-treated patients are currently experiencing these side effects, signifying either their transient nature or the effective medical management of such events. In the end, fewer than 15 percent of surveyed neurologists felt that Tecfidera-related side effects were an obstacle to their prescribing of the product.
Stocks Climb In Solid Trade; Chipotle Gaps Up, Breaks Out
at Investor's Business Daily - Tue Jul 22, 9:32AM CDT
Stocks stepped higher in firm volume Tuesday on a generally positive swell of earnings and economic news. The Nasdaq jumped 0.9% in early trade, with biotechs Alexion Pharmaceuticals (ALXN), Celgene (CELG) and Biogen (BIIB) leading the Nasdaq 100....
Is a Surprise Coming for Biogen Idec (BIIB) This Earnings Season? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 22, 7:44AM CDT
Biogen Idec (BIIB) looks poised to beat at earnings season. That is because Biogen Idec is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Oil Dominates; Keurig, Constellation Near Buy Points
at Investor's Business Daily - Mon Jul 21, 5:51PM CDT
Notable names dropping out of the Big Cap 20 this week include Biogen (BIIB) and Chipotle Mexican Grill (CMG), while new entrants include Canadian Pacific Railway (CP) and Magna International (MGA). Oil and gas continue to dominate this week's list,...
Isis Pharma Initiates Phase II Study on ISIS-APO(a) - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 21, 5:50PM CDT
Isis Pharmaceuticals, Inc. (ISIS) initiated a phase II study on ISIS-APO(a) in patients suffering from high lipoprotein(a) -- Lp(a).
IBD 50 Ends Week Lower But Skyworks Soars
at Investor's Business Daily - Mon Jul 21, 5:47PM CDT
The IBD 50 fell for a second straight week amid the market's recent turbulence as biotech stocks sold off. But many leading stocks continue to hold up well, and few have flashed sell signals. The index of top growth stocks fell 0.6% for the week,...
Alkermes' Pipeline Development Impresses, Key Updates Ahead - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 21, 3:40PM CDT
Alkermes (ALKS) announced the commencement of a phase I study on ALKS 8700.
Biogen Shares Rebound As Street Has A Change Of Heart
at Investor's Business Daily - Mon Jul 21, 3:09PM CDT
Biogen Idec heads into its second-quarter earnings report on one of its best rolls in years, as the biotech continues to benefit from heavy demand for its drugs to treat multiple sclerosis, cancer and autoimmune diseases. The No. 3 biotech by market...
Yellen Hates Biotech Stocks! Should You?
Brian Orelli, The Motley Fool - Motley Fool - Mon Jul 21, 1:01PM CDT
Federal Reserve Chairwoman Janet Yellen thinks your small-cap biotech is overvalued. The Fed's Monetary Policy Report, released on July 15, had this to say: [V]aluation metrics in some sectors do appear substantially stretched -- particularly...
Amgen's AMG 416 Succeeds in Phase III, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 21, 12:23PM CDT
Amgen Inc. (AMGN) announced that AMG 416 (formerly known as velcalcetide) has met the primary as well as secondary endpoints in a phase III study.
Ultragenyx (RARE) Jumps: Stock Moves 7.8% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 21, 8:25AM CDT
Ultragenyx (RARE) was a big mover last session, with shares rising nearly 8% on the day.
bluebird bio, Inc. (BLUE) in Focus: Stock Surges 10.24% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 21, 7:44AM CDT
bluebird bio, Inc. (BLUE) was a big mover last session, as the company saw its shares surge over 10% on the day.
Facebook, Gilead Headline IBD 50's Top 5 Earnings
at Investor's Business Daily - Sat Jul 19, 7:02AM CDT
With earnings season in full force, investors should focus on the very best companies. The elite IBD 50 ranks top-rated growth stocks, factoring in strong relative price strength and top fundamentals. The IBD 50 has several companies reporting...
Why the Market is Wrong About Baxter Stock
Stephen D., Simpson,, The Motley Fool - Motley Fool - Fri Jul 18, 7:59AM CDT
Diversified health care player Baxter has done alright so far this year, up almost 10% and ahead of the S&P 500, but there is still a fair bit of skepticism on the name. Analysts continue to fret that Biogen Idec ...
